Heart Test Laboratories announces publication on use of MyoVista technology

Heart Test Laboratories announced the publication, in Cardiovascular Diabetology, of an independent, peer-reviewed study utilizing its MyoVista proprietary technology. Recent guidelines propose N-terminal pro-B-type natriuretic peptide for recognition of asymptomatic left ventricular dysfunction in type 2 diabetes patients. Accordingly, the study sought to evaluate whether an AI-ECG model based on MyoVista wavECG features was superior to NT-proBNP, as well as a conventional screening tool-the Atherosclerosis Risk in Communities HF risk score, in SBHF screening among patients with T2DM. The authors of the publication stated, “Among patients with T2DM, the accuracy of ewECG model in SBHF screening was shown to be significantly higher than both NT-proBNP and the ARIC HF risk score,” and concluded, “Machine learning based modelling using additional ewECG extracted features are superior to NT-proBNP and ARIC HF in SBHF screening among patients with T2DM, providing an alternative HF screening strategy for asymptomatic patients and potentially act as a guidance tool to determine those who required echocardiogram to confirm diagnosis.”